Title:
USE OF AROMATIC FUSED RING COMPOUND AS TREK-1 ACTIVATOR, AND PHARMACEUTICAL COMPOSITION AND ANALGESIC CONTAINING SAME
Document Type and Number:
WIPO Patent Application WO/2023/213198
Kind Code:
A1
Abstract:
The present invention provides the following compound (I) or a pharmaceutically acceptable salt, ester, optical isomer, stereoisomer, or metabolite thereof, and a pharmaceutical composition containing the compound of the present invention, further provides a use of the compound of the present invention as an activator of a TREK-1 potassium ion channel, and an application in reducing and/or eliminating pain, and also provides an application of the compound of the present invention in the preparation of analgesic drugs. The present invention also provides a treatment method for diseases related to the TREK-1 potassium ion channel.
Inventors:
YANG HUAIYU (CN)
YE YANGLIANG (CN)
LI JUNNAN (CN)
MO YIQING (CN)
YAN YUQIAN (CN)
MEI LIANGHE (CN)
ZHANG QIANSEN (CN)
SHEN JUWEN (CN)
QIAN LINYI (CN)
YE YANGLIANG (CN)
LI JUNNAN (CN)
MO YIQING (CN)
YAN YUQIAN (CN)
MEI LIANGHE (CN)
ZHANG QIANSEN (CN)
SHEN JUWEN (CN)
QIAN LINYI (CN)
Application Number:
PCT/CN2023/089862
Publication Date:
November 09, 2023
Filing Date:
April 21, 2023
Export Citation:
Assignee:
UNIV EAST CHINA NORMAL (CN)
SUZHOU ALPHAMA BIOTECHNOLOGY CO LTD (CN)
SUZHOU ALPHAMA BIOTECHNOLOGY CO LTD (CN)
International Classes:
C07D487/04; A61K31/519; A61P19/02; A61P21/00; A61P25/04; A61P29/00; A61P35/00
Foreign References:
| CN114432315A | 2022-05-06 | |||
| CN1334816A | 2002-02-06 | |||
| CN103275087A | 2013-09-04 | |||
| CN103864794A | 2014-06-18 | |||
| CN1270590A | 2000-10-18 | |||
| CN109689061A | 2019-04-26 | |||
| CN111386271A | 2020-07-07 | |||
| CN102924457A | 2013-02-13 | |||
| CN104672242A | 2015-06-03 | |||
| CN110698482A | 2020-01-17 | |||
| CN110746428A | 2020-02-04 | |||
| US20080188483A1 | 2008-08-07 | |||
| US20170197965A1 | 2017-07-13 |
Other References:
ERIC GOFFIN ET AL.: "Synthesis of Ticagrelor Analogues Belonging to 1,2,3-triazolo[4,5-d]pyrimidines and Study of Their Antiplatelet and Antibacterial Activity", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 208, 23 August 2020 (2020-08-23), XP086345788, DOI: 10.1016/j.ejmech.2020.112767
ZHONG WANPING, WANG XIPEI, TANG LAN, MAI LIPING, CHEN XIAO-PING, HE GUODONG, ZHENG ZHIJIE, ZHONG SHILONG: "Simultaneous Determination of Ticagrelor and Its Metabolites in Human Plasma and Urine Using Liquid Chromatography–Tandem Mass Spectrometry", JOURNAL OF ANALYTICAL TOXICOLOGY, PRESTON PUBLICATIONS, INC., US, vol. 40, no. 6, 1 July 2016 (2016-07-01), US , pages 445 - 453, XP093105672, ISSN: 0146-4760, DOI: 10.1093/jat/bkw039
HASSANE SADOU YAYE ET AL.: "Identification of the Major Degradation Pathways of Ticagrelor", JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, vol. 105, 4 December 2014 (2014-12-04), XP029130906, DOI: 10.1016/j.jpba.2014.11.046
DATABASE Registry 22 December 2021 (2021-12-22), ANONYMOUS: "1,2-Cyclopentanediol, 3-[7-[[(1R,2S)-2-(3,4- difluorophenyl)cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5- d]pyrimidin-3-yl]-5-(2-iodoethoxy)-, (1S,2S,3R,5S)- (CA INDEX NAME)", XP093105720, retrieved from STNext Database accession no. 2750168-80-8
DATABASE Registry 26 June 2020 (2020-06-26), ANONYMOUS: "1,2,3-Cyclopentanetriol, 4-[7-[[(1R)-2-(3,4- difluorophenyl)cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5- d]pyrimidin-3-yl]-, (1S,2S,3R,4R)-rel- (CA INDEX NAME)", XP093105721, retrieved from STNext Database accession no. 2434860-97-4
DATABASE Registry. 21 February 2019 (2019-02-21), ANONYMOUS: "1,2-Cyclopentanediol, 3-[7-[[(1R,2S)-2-(3,4- difluorophenyl)cyclopropyl]amino]-5-(2-propen-1-ylthio)-3H-1,2,3- triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)-, (1S,2S,3R,5S)- (CA INDEX NAME)", XP093105722, Database accession no. 2271293-30-0
DATABASE Registry 10 June 2019 (2019-06-10), ANONYMOUS: "1,2-Cyclopentanediol, 3-(2-bromoethoxy)-5-[7-[[(1R,2S)-2-(3,4- difluorophenyl)cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5- d]pyrimidin-3-yl]-, (1S,2S,3S,5R)- (CA INDEX NAME)", XP093105723, retrieved from STNext Database accession no. 2307234-01-9
ZHONG WANPING, WANG XIPEI, TANG LAN, MAI LIPING, CHEN XIAO-PING, HE GUODONG, ZHENG ZHIJIE, ZHONG SHILONG: "Simultaneous Determination of Ticagrelor and Its Metabolites in Human Plasma and Urine Using Liquid Chromatography–Tandem Mass Spectrometry", JOURNAL OF ANALYTICAL TOXICOLOGY, PRESTON PUBLICATIONS, INC., US, vol. 40, no. 6, 1 July 2016 (2016-07-01), US , pages 445 - 453, XP093105672, ISSN: 0146-4760, DOI: 10.1093/jat/bkw039
HASSANE SADOU YAYE ET AL.: "Identification of the Major Degradation Pathways of Ticagrelor", JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, vol. 105, 4 December 2014 (2014-12-04), XP029130906, DOI: 10.1016/j.jpba.2014.11.046
DATABASE Registry 22 December 2021 (2021-12-22), ANONYMOUS: "1,2-Cyclopentanediol, 3-[7-[[(1R,2S)-2-(3,4- difluorophenyl)cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5- d]pyrimidin-3-yl]-5-(2-iodoethoxy)-, (1S,2S,3R,5S)- (CA INDEX NAME)", XP093105720, retrieved from STNext Database accession no. 2750168-80-8
DATABASE Registry 26 June 2020 (2020-06-26), ANONYMOUS: "1,2,3-Cyclopentanetriol, 4-[7-[[(1R)-2-(3,4- difluorophenyl)cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5- d]pyrimidin-3-yl]-, (1S,2S,3R,4R)-rel- (CA INDEX NAME)", XP093105721, retrieved from STNext Database accession no. 2434860-97-4
DATABASE Registry. 21 February 2019 (2019-02-21), ANONYMOUS: "1,2-Cyclopentanediol, 3-[7-[[(1R,2S)-2-(3,4- difluorophenyl)cyclopropyl]amino]-5-(2-propen-1-ylthio)-3H-1,2,3- triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)-, (1S,2S,3R,5S)- (CA INDEX NAME)", XP093105722, Database accession no. 2271293-30-0
DATABASE Registry 10 June 2019 (2019-06-10), ANONYMOUS: "1,2-Cyclopentanediol, 3-(2-bromoethoxy)-5-[7-[[(1R,2S)-2-(3,4- difluorophenyl)cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5- d]pyrimidin-3-yl]-, (1S,2S,3S,5R)- (CA INDEX NAME)", XP093105723, retrieved from STNext Database accession no. 2307234-01-9
Attorney, Agent or Firm:
FIWIS INTELLECTUAL PROPERTY LAW FIRM et al. (CN)
Download PDF: